Abstract
Introduction: Meta-analyses of real-world evidence (RWE) studies provide valuable insights from unselected patient populations in routine clinical practice. Secukinumab, the first fully human monoclonal antibody that selectively neutralizes IL-17A, has shown long lasting effectiveness and safety in moderate to severe plaque psoriasis (PsO). Since its license approval in 2015, many RWE studies have been published. Here, we reviewed all available literature on RWE studies involving secukinumab in patients with moderate to severe PsO to evaluate its effectiveness, drug survival and safety.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
